retatrutide phase 2 diabetes trial VisualAbstract: reduces body weight by 17.5% in patients with obesity A new weight-loss drug called
Description
32 Elafibranor (GFT505) is the first member of the PPAR-/PPAR- agonist family
What does the future look like
Instead of replacing GLP-1 or encouraging unnaturally high levels, its designed to: Support your bodys own GLP-1 signaling* Reinforce fullness cues rather than override them* Work gradually and sustainably* Different tools
How to Balance It Stick to one moderate cup per day
appropriate monitoring is recommended
